China Pharma Holdings, Inc. (CPHI)
USD 0.17
(-9.78%)
USD 0.17
(-9.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8436.00 USD | 100.22% |
| 2022 | -837.68 Thousand USD | -3311.52% |
| 2021 | 230.34 Thousand USD | -111.2% |
| 2020 | 106.85 Thousand USD | 151.25% |
| 2019 | -17.45 Million USD | 38.95% |
| 2018 | -7.15 Million USD | 41.1% |
| 2017 | -15.32 Million USD | -8.02% |
| 2016 | -4.94 Million USD | 89.48% |
| 2015 | -10.58 Million USD | 69.51% |
| 2014 | -36.9 Million USD | -161.48% |
| 2013 | -16.98 Million USD | -266.99% |
| 2012 | 7.37 Million USD | -65.7% |
| 2011 | 24.14 Million USD | -11.37% |
| 2010 | 27.77 Million USD | 9.04% |
| 2009 | 24.01 Million USD | 16.84% |
| 2008 | 20.39 Million USD | 70.39% |
| 2007 | 12.67 Million USD | 35.35% |
| 2006 | 9.02 Million USD | 98.02% |
| 2005 | 4.49 Million USD | 485.89% |
| 2004 | 768.14 Thousand USD | 1303.26% |
| 2003 | 386.82 Thousand USD | 78.14% |
| 2002 | -383.44 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -916.05 Thousand USD | 62.98% |
| 2024 Q2 | -649.88 Thousand USD | -260.31% |
| 2023 Q2 | 243.52 Thousand USD | -13.77% |
| 2023 FY | - USD | 100.22% |
| 2023 Q1 | 282.4 Thousand USD | 153.33% |
| 2023 Q3 | -713.54 Thousand USD | -393.01% |
| 2023 Q4 | -488.65 Thousand USD | 31.52% |
| 2022 Q2 | -96.37 Thousand USD | 51.36% |
| 2022 Q3 | -96.29 Thousand USD | 0.09% |
| 2022 FY | - USD | -3311.52% |
| 2022 Q1 | -198.16 Thousand USD | -419.48% |
| 2022 Q4 | -529.58 Thousand USD | -449.96% |
| 2021 FY | - USD | -111.2% |
| 2021 Q1 | 3719.00 USD | 100.93% |
| 2021 Q2 | -52.48 Thousand USD | -1511.35% |
| 2021 Q3 | 214.05 Thousand USD | 507.81% |
| 2021 Q4 | 62.02 Thousand USD | -71.02% |
| 2020 Q1 | 56.64 Thousand USD | 105.7% |
| 2020 FY | - USD | 151.25% |
| 2020 Q3 | -279.2 Thousand USD | -138.56% |
| 2020 Q2 | 724.13 Thousand USD | 1178.46% |
| 2020 Q4 | -400.39 Thousand USD | -43.41% |
| 2019 Q1 | 461.27 Thousand USD | 269.46% |
| 2019 FY | - USD | 38.95% |
| 2019 Q3 | 40.72 Thousand USD | 48.53% |
| 2019 Q2 | 27.41 Thousand USD | -94.06% |
| 2019 Q4 | -993.35 Thousand USD | -2539.12% |
| 2018 FY | - USD | 41.1% |
| 2018 Q4 | -272.2 Thousand USD | 76.26% |
| 2018 Q3 | -1.14 Million USD | -9866.52% |
| 2018 Q2 | -11.5 Thousand USD | -101.6% |
| 2018 Q1 | 720.74 Thousand USD | 187.34% |
| 2017 Q2 | -340.48 Thousand USD | -2768.14% |
| 2017 Q3 | -51.77 Thousand USD | 84.79% |
| 2017 Q4 | -825.22 Thousand USD | -1493.96% |
| 2017 FY | - USD | -8.02% |
| 2017 Q1 | 12.76 Thousand USD | 117.07% |
| 2016 Q4 | -74.77 Thousand USD | -54.76% |
| 2016 FY | - USD | 89.48% |
| 2016 Q1 | -464.15 Thousand USD | 90.88% |
| 2016 Q2 | -528 Thousand USD | -13.76% |
| 2016 Q3 | -48.31 Thousand USD | 90.85% |
| 2015 Q4 | -5.08 Million USD | -224.76% |
| 2015 Q2 | -2.87 Million USD | 57.27% |
| 2015 Q1 | -6.71 Million USD | 68.31% |
| 2015 FY | - USD | 69.51% |
| 2015 Q3 | 4.07 Million USD | 242.1% |
| 2014 Q1 | -2.03 Million USD | 47.55% |
| 2014 Q2 | -8.22 Million USD | -303.89% |
| 2014 Q3 | -3.29 Million USD | 59.91% |
| 2014 Q4 | -21.19 Million USD | -542.43% |
| 2014 FY | - USD | -161.48% |
| 2013 Q1 | -2.64 Million USD | -601.17% |
| 2013 Q2 | -4.41 Million USD | -66.56% |
| 2013 Q3 | -2.34 Million USD | 46.86% |
| 2013 Q4 | -3.88 Million USD | -65.63% |
| 2013 FY | - USD | -266.99% |
| 2012 Q4 | -377.93 Thousand USD | -119.04% |
| 2012 FY | - USD | -65.7% |
| 2012 Q3 | 1.98 Million USD | -22.88% |
| 2012 Q2 | 2.57 Million USD | -31.89% |
| 2012 Q1 | 3.77 Million USD | -47.34% |
| 2011 FY | - USD | -11.37% |
| 2011 Q4 | 7.17 Million USD | 16.6% |
| 2011 Q3 | 6.15 Million USD | 3.5% |
| 2011 Q2 | 5.94 Million USD | 2.84% |
| 2011 Q1 | 5.78 Million USD | -29.23% |
| 2010 Q4 | 8.17 Million USD | 21.36% |
| 2010 Q3 | 6.73 Million USD | 13.79% |
| 2010 FY | - USD | 9.04% |
| 2010 Q2 | 5.91 Million USD | 12.62% |
| 2010 Q1 | 5.25 Million USD | -13.66% |
| 2009 Q2 | 5.11 Million USD | 18.05% |
| 2009 FY | - USD | 16.84% |
| 2009 Q4 | 6.08 Million USD | -28.26% |
| 2009 Q3 | 8.48 Million USD | 65.89% |
| 2009 Q1 | 4.33 Million USD | -30.32% |
| 2008 Q2 | 4.64 Million USD | -3.62% |
| 2008 Q4 | 6.21 Million USD | -40.09% |
| 2008 FY | - USD | 70.39% |
| 2008 Q3 | 10.37 Million USD | 123.55% |
| 2008 Q1 | 4.81 Million USD | -17.17% |
| 2007 FY | - USD | 35.35% |
| 2007 Q4 | 5.81 Million USD | 79.66% |
| 2007 Q1 | -447.98 Thousand USD | -115.97% |
| 2007 Q2 | 3.45 Million USD | 872.13% |
| 2007 Q3 | 3.23 Million USD | -6.43% |
| 2006 Q2 | 711.27 Thousand USD | -62.9% |
| 2006 Q1 | 1.91 Million USD | 0.0% |
| 2006 Q3 | 2.16 Million USD | 204.81% |
| 2006 Q4 | 2.8 Million USD | 29.43% |
| 2006 FY | - USD | 98.02% |
| 2005 Q2 | -1.77 Million USD | -3782.88% |
| 2005 FY | - USD | 485.89% |
| 2005 Q1 | -45.67 Thousand USD | -163.17% |
| 2005 Q3 | 765.35 Thousand USD | 143.15% |
| 2004 Q3 | -10.72 Thousand USD | -140.92% |
| 2004 Q4 | -17.35 Thousand USD | -61.85% |
| 2004 FY | - USD | 1303.26% |
| 2004 Q2 | 26.21 Thousand USD | 648.43% |
| 2004 Q1 | 3502.00 USD | 722.02% |
| 2003 Q4 | -563.00 USD | -100.24% |
| 2003 Q2 | -33.13 Thousand USD | 8.63% |
| 2003 Q1 | -36.26 Thousand USD | 42.05% |
| 2003 Q3 | 229.8 Thousand USD | 793.57% |
| 2003 FY | - USD | 78.14% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | -62.57 Thousand USD | -191.84% |
| 2002 Q3 | 68.13 Thousand USD | 166.94% |
| 2002 Q2 | -101.79 Thousand USD | 68.7% |
| 2002 Q1 | -325.24 Thousand USD | -401.38% |
| 2001 Q4 | -64.87 Thousand USD | 53.54% |
| 2001 Q3 | -139.62 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| cbdMD, Inc. | -7.46 Million USD | 100.113% |
| cbdMD, Inc. | -7.46 Million USD | 100.113% |
| Zomedica Corp. | -29.38 Million USD | 100.029% |